Pan-cancer analysis and experimental verification of cytochrome B561 as a prognostic and therapeutic biomarker in breast cancer.

IF 2.8 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Discover. Oncology Pub Date : 2025-03-17 DOI:10.1007/s12672-025-02094-1

Xiaoting Qiu, Peizhang Liu, Hongxiang Lin, Zeyi Peng, Xinhao Sun, Guanting Dong, Yuanyuan Han, Zhijian Huang

{"title":"Pan-cancer analysis and experimental verification of cytochrome B561 as a prognostic and therapeutic biomarker in breast cancer.","authors":"Xiaoting Qiu, Peizhang Liu, Hongxiang Lin, Zeyi Peng, Xinhao Sun, Guanting Dong, Yuanyuan Han, Zhijian Huang","doi":"10.1007/s12672-025-02094-1","DOIUrl":null,"url":null,"abstract":"Objective: This study investigates Cytochrome B561 (CYB561) expression in Pan-Cancer, its relationship with immune invasion, and its prognostic value in Breast Cancer (BRCA) patients.Methods: Data from The Cancer Genome Atlas (TCGA) were analyzed. CYB561 expression in normal and tumor tissues was examined, with correlations to immune invasion, mutation, and immune checkpoints. Wilcoxon rank-sum test assessed expression differences. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted. Logistic regression, Kaplan-Meier, and Cox regression analyses evaluated clinicopathological features and survival outcomes. A Cox multivariate analysis-based Nomogram predicted CYB561's prognostic impact. CYB561 knockout in breast cancer cells assessed functional effects. Single-cell RNA sequencing identified prognostic biomarkers.Results: CYB561 was highly expressed in most tumors. BRCA showed the highest correlation with ESTIMATE scores and significant negative correlation with immune checkpoints. High CYB561 expression correlated with specific clinicopathological features and survival outcomes. The nomogram predicted BRCA prognosis. CYB561 knockout inhibited breast cancer cell proliferation. Seven predictive agents for CYB561 inhibition were identified.Conclusions: CYB561 exhibits aberrant expression in tumors, particularly in BRCA, and serves as a predictive marker for immune-related therapies and a prognostic indicator in BRCA.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"330"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911281/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-02094-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study investigates Cytochrome B561 (CYB561) expression in Pan-Cancer, its relationship with immune invasion, and its prognostic value in Breast Cancer (BRCA) patients.

Methods: Data from The Cancer Genome Atlas (TCGA) were analyzed. CYB561 expression in normal and tumor tissues was examined, with correlations to immune invasion, mutation, and immune checkpoints. Wilcoxon rank-sum test assessed expression differences. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted. Logistic regression, Kaplan-Meier, and Cox regression analyses evaluated clinicopathological features and survival outcomes. A Cox multivariate analysis-based Nomogram predicted CYB561's prognostic impact. CYB561 knockout in breast cancer cells assessed functional effects. Single-cell RNA sequencing identified prognostic biomarkers.

Results: CYB561 was highly expressed in most tumors. BRCA showed the highest correlation with ESTIMATE scores and significant negative correlation with immune checkpoints. High CYB561 expression correlated with specific clinicopathological features and survival outcomes. The nomogram predicted BRCA prognosis. CYB561 knockout inhibited breast cancer cell proliferation. Seven predictive agents for CYB561 inhibition were identified.

Conclusions: CYB561 exhibits aberrant expression in tumors, particularly in BRCA, and serves as a predictive marker for immune-related therapies and a prognostic indicator in BRCA.

查看原文本刊更多论文

研究目的本研究探讨了细胞色素 B561（CYB561）在泛癌中的表达、其与免疫侵袭的关系及其在乳腺癌（BRCA）患者中的预后价值：方法：分析癌症基因组图谱（TCGA）中的数据。方法：对癌症基因组图谱（TCGA）中的数据进行分析，研究正常组织和肿瘤组织中 CYB561 的表达，以及其与免疫侵袭、基因突变和免疫检查点的相关性。Wilcoxon 秩和检验评估了表达差异。进行了基因本体（GO）和京都基因与基因组百科全书（KEGG）分析。逻辑回归、Kaplan-Meier和Cox回归分析评估了临床病理特征和生存结果。基于Cox多变量分析的Nomogram预测了CYB561对预后的影响。在乳腺癌细胞中敲除 CYB561 可评估其功能效应。单细胞RNA测序确定了预后生物标志物：结果：CYB561在大多数肿瘤中高表达。BRCA与ESTIMATE评分的相关性最高，与免疫检查点呈显著负相关。CYB561的高表达与特定的临床病理特征和生存结果相关。提名图预测了 BRCA 的预后。CYB561 基因敲除可抑制乳腺癌细胞增殖。结论：CYB561在乳腺癌细胞增殖中表现出异常：CYB561在肿瘤中异常表达，尤其是在BRCA中，可作为免疫相关疗法的预测标志物和BRCA的预后指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊